Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors

被引:27
|
作者
Breuker, Cyril [1 ,2 ]
Clement, Florian [1 ]
Mura, Thibault [3 ]
Macioce, Valerie [3 ]
Castet-Nicolas, Audrey [1 ,5 ]
Audurier, Yohan [1 ]
Boegner, Catherine [4 ]
Morcrette, Emilie [4 ]
Jalabert, Anne [1 ]
Villiet, Maxime [1 ]
Avignon, Antoine [2 ,4 ]
Sultan, Ariane [2 ,4 ]
机构
[1] Univ Hosp, Clin Pharm Dept, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier, France
[2] Univ Montpellier, CNRS, INSERM, PhyMedExp, Montpellier, France
[3] Univ Hosp, Clin Res & Epidemiol Unit, Montpellier, France
[4] Univ Hosp, Endocrinol Diabetol Nutr Dept, Montpellier, France
[5] Univ Montpellier, IRCM INSERM U1194, Montpellier, France
关键词
Type; 2; diabetes; Low-density lipoprotein cholesterol; Cardiovascular risk; Lipid-lowering therapy; ESC/EAS GUIDELINES; LOWERING THERAPY; MANAGEMENT; DISEASE; INTERVENTIONS; DYSLIPIDEMIA; ASSOCIATION; ATTAINMENT; ADHERENCE; PEOPLE;
D O I
10.1016/j.ijcard.2018.04.068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiovascular diseases are the first cause of mortality in patients with diabetes, and LDL-cholesterol is a well-established cardiovascular risk factor. This study aimed to assess rate of LDL-cholesterol target attainment among patients with diabetes at very-high cardiovascular risk treated with statins, and to identify predictive factors of non-attainment of target in this population. Methods: Patients were recruited in the Nutrition-Diabetes unit of Montpellier University Hospital, France, from 2014 to 2017. We included all consecutive patients with type 1 or type 2 diabetes receiving statin treatment and at very-high cardiovascular risk according to 2016 ESC guidelines, therefore having a LDL-cholesterol target of <1.8 mmol/L. LDL-cholesterol levels were measured upon admission. Variables independently associated with non-attainment of LDL-Cholesterol target were assessed using multivariable logistic regression. Results: 654 patients were included. Mean age was 63.8 years (SD 11.0), 41.9% were women and 42.3% had a history of cardiovascular disease. 59% of patients did not achieve LDL-cholesterol target, with a median value (inter-quartile range) of 2.4 mmol/L (2.1-2.9) versus 1.4 mmol/L (1.1-1.6) in patients at target. Risk of non-attainment of LDL-cholesterol target value was increased in women (odds ratio [95% confidence interval]: 2.27 [1.62-3.17]) and decreased in patients with history of coronary artery disease (0.64 [0.45-0.89]) or history of stroke or transient ischemic attack (0.59 [0.33-1.07]). Conclusions: Management of dyslipidemia is suboptimal, even in very-high risk patients with diabetes under statins. Lipid-lowering treatment should be intensified, in particular in very high risk patients with diabetes who are women or in primary cardiovascular prevention. (c) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:195 / 199
页数:5
相关论文
共 50 条
  • [41] Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis
    Salem, Ahmed M.
    Harris, Daniel
    Obaid, Daniel R.
    Stephens, Jeffrey W.
    Halcox, Julian
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 377 : 104 - 111
  • [42] Treatment and low-density lipoprotein cholesterol levels in patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular risk: a population-based cross-sectional study in the Netherlands
    Heintjes, Edith M.
    Anastassopoulou, Anastassia
    Kuiper, Josephina
    Bilitou, Aikaterini
    Penning-van Beest, Fernie J. A.
    Herings, Ron M. C.
    Postma, Maarten J.
    Jukema, J. Wouter
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (01) : 1 - 11
  • [43] Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
    Julius L. Katzmann
    Francesc Sorio-Vilela
    Eugen Dornstauder
    Uwe Fraas
    Timo Smieszek
    Sofia Zappacosta
    Ulrich Laufs
    Clinical Research in Cardiology, 2022, 111 : 243 - 252
  • [44] Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Espanola de Cardiologia [Spanish Society of Cardiology] and the Sociedad Espanola de Diabetes [Spanish Diabetes Society]
    Pedro-Botet, Juan
    Barrios, Vivencio
    Sanchez-Margalet, Victor
    Tamargo, Juan
    Arrieta, Francisco
    Ma Gamez, Jose
    Gimeno-Orna, Jose Antonio
    Escobar, Carlos
    Gomez-Doblas, Juan Jose
    Perez, Antonio
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2023, 70 : 51 - 62
  • [45] Ezetimibe in Prevention of Cerebro- and Cardiovascular Events in Middle- to High-Risk, Elderly (75 Years Old or Over) Patients With Elevated LDL-Cholesterol: A Multicenter, Randomized, Controlled, Open-Label Trial
    Arai, Hidenori
    Sasaki, Jun
    Yokote, Koutaro
    Kuwabara, Masanari
    Harada, Kazumasa
    Imai, Takumi
    Tanaka, Shiro
    Ohashi, Yasuo
    Ito, Hideki
    Ouchi, Yasuyoshi
    CIRCULATION, 2018, 138 (25) : E753 - E753
  • [46] Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes: A systematic review and meta-analysis
    Cao, Yanchao
    Yan, Liqiu
    Guo, Nan
    Yu, Na
    Wang, Yunfei
    Cao, Xufen
    Yang, Shuping
    Lv, Fengfeng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 147 : 1 - 8
  • [47] 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
    Lloyd-Jones, Donald M.
    Morris, Pamela B.
    Ballantyne, Christie M.
    Birtcher, Kim K.
    Daly, David D., Jr.
    DePalma, Sondra M.
    Minissian, Margo B.
    Orringer, Carl E.
    Smith, Sidney C., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (14) : 1785 - 1822
  • [48] Very high HDL-C (high-density lipoprotein cholesterol) is associated with increased cardiovascular risk in patients with NSTEMI (non-ST-segment elevation myocardial infarction) undergoing PCI (percutaneous coronary intervention)
    Chen, Lijuan
    Zhao, Yuanyuan
    Wang, Zheng
    Wang, Yifei
    Bo, Xiangwei
    Jiang, Xiaoxi
    Hao, Chunshu
    Ju, Chengwei
    Qu, Yangyang
    Dong, Hongjian
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [49] Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension
    Grassi, Guido
    Del Pinto, Rita
    Agabiti Rosei, Claudia
    Agnoletti, Davide
    Borghi, Claudio
    Cicero, Arrigo F. G.
    De Ciuceis, Carolina
    Desideri, Giovambattista
    Grassi, Davide
    Muiesan, Maria Lorenza
    Paini, Anna
    Salvetti, Massimo
    Tocci, Giuliano
    Veglio, Franco
    Volpe, Massimo
    Ferri, Claudio
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2022, 29 (02) : 105 - 113
  • [50] Achieving LDL cholesterol target levels &lt;1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study
    Itoh, Hiroshi
    Komuro, Issei
    Takeuchi, Masahiro
    Akasaka, Takashi
    Daida, Hiroyuki
    Egashira, Yoshiki
    Fujita, Hideo
    Higaki, Jitsuo
    Hirata, Ken-ichi
    Ishibashi, Shun
    Isshiki, Takaaki
    Ito, Sadayoshi
    Kashiwagi, Atsunori
    Kato, Satoshi
    Kitagawa, Kazuo
    Kitakaze, Masafumi
    Kitazono, Takanari
    Kurabayashi, Masahiko
    Miyauchi, Katsumi
    Murakami, Tomoaki
    Murohara, Toyoaki
    Node, Koichi
    Ogawa, Susumu
    Saito, Yoshihiko
    Seino, Yoshihiko
    Shigeeda, Takashi
    Shindo, Shunya
    Sugawara, Masahiro
    Sugiyama, Seigo
    Terauchi, Yasuo
    Tsutsui, Hiroyuki
    Ueshima, Kenji
    Utsunomiya, Kazunori
    Yamagishi, Masakazu
    Yamazaki, Tsutomu
    Yo, Shoei
    Yokote, Koutaro
    Yoshida, Kiyoshi
    Yoshimura, Michihiro
    Yoshimura, Nagahisa
    Nakao, Kazuwa
    Nagai, Ryozo
    DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 791 - 800